Tackling the elusive challenges relevant to conquering the 100-plus year old problem of Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 1, 2013, Pages 108-116

  Colom, Luis V ^a   Perry, George ^b   Kuljiš, Rodrigo O ^c,d,e,f,g  

^a UNIVERSITY OF TEXAS AT BROWNSVILLE   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c Encephalogistics Inc   (United States)

^d Brain Mind Project Inc   (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f Instituto Neurogeriátrico   (Chile)

^g UNIVERSITY OF CHILE   (Chile)

Author keywords

Aging; Alzheimer's disease; Amyloid; Basal forebrain; Brain dysfunction; Dementia; Neurodegeneration; Potassium channels

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; POTASSIUM CHANNEL; AMYLOID BETA PROTEIN;

AGING; ALGORITHM; ALZHEIMER DISEASE; ANIMAL MODEL; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; BRAIN REGION; CLINICAL PATHWAY; COGNITION; DEMENTIA; EPILEPSY; FEEDBACK SYSTEM; HUMAN; MENTAL HEALTH RESEARCH; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE EXCITABILITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; BIOLOGICAL MODEL; BRAIN; HISTORY; MEDICAL RESEARCH; METABOLISM; METHODOLOGY; PATHOLOGY; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMEDICAL RESEARCH; BRAIN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MODELS, BIOLOGICAL;

EID: 84882427587     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720513804871408     Document Type: Article

References (72)

1. Alzheimer A. A singular disorder that affects the cerebral cortex. 1907. In: Hochberg, CN y Hochberg, FH,. Neurologic Classics in Modern Translation. New York: Hafner Press. 41-43 (1977).
2. Perry G, Zhu X, Smith MA. Do neurons have a choice in death? Am J Pathol 158(1): 1-2 (2001).
3. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose. Am J Pathol 169(3): 738-739 (2006).
4. Kuljis RO. A multi-dimensional formulation of the pathogenesis and pathophysiology of the Alzheimer dementia-like syndrome applicable to a variety of degenerative disorders and normal cognition. Med Hypotheses 73(3): 315-318 (2009).
5. Kuljis RO. Grand challenges in dementia 2010. Frontiers in Neurology - Dementia (a specialty of Frontiers in Neurology). 1: 4 (2010).
6. Kuljis RO. Integrative understanding of emergent brain properties, Quantum Brain hypotheses and Connectome alterations are key challenges to conquer Alzheimer's disease. Frontiers in Neurology - Dementia (a specialty of Frontiers in Neurology) 1: 15 (2010).
7. Kuljis RO. The Fourth Element Targeting hypothesis of Alzheimer's disease pathogenesis and pathophysiology. Frontiers in Neurology - Dementia (a specialty of Frontiers in Neurology). 2010.
8. Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer's disease. Bio-med Pharmacother 62(4): 199-207 (2011).
9. Smith MA, Atwood CS, Joseph JA, Perry G. Ill-fated amyloid-β vaccine. J Neurosci Res 69(3): 285 (2002).
10. Puzzo D, Privitera L, Fa' M, Staniszewski A, Hashimoto G, Aziz F, et al. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69(5): 819-830 (2011).
11. Hoe HS, Lee HK, Pak DT. The upside of APP at synapses. CNS Neurosci Ther 18(1): 47-56 (2012).
12. Glenner GG, Wong CG. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3): 885-890 (1984).
13. Ashe KH. In search for the molecular basis of memory loss in Alzheimer's disease. Alzheimer Dis Assoc Disord 20(4): 200-201 (2006).
14. Ashe KH, Sahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 66: 631-645 (2010).
15. Sahs KR, Ashe KH. 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci 33: 381-389 (2010).
16. Geerts H. Of mice and men. Bridging the translational disconnect in CNS drug discovery. CNS Drugs 23(11): 915-926 (2010).
17. Ferretti MT, Partridge V, Leon WC, Canneva F, Allard S, Arvanitis DN, et al. Transgenic Mice as a Model of Pre-Clinical Alzheimer's Disease. Curr Alzheimer Res 8(1): 4-23 (2010).
18. Piermartiri TC, Figueiredo CP, Rial D, Duarte FS, Bezerra SC, Mancini G, et al. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β (1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol 226(2): 274-284 (2010).
19. Driscoll I, Troncoso J. Asymptomatic Alzheimer's disease: a prodrome or a state of resilience? Curr Alzheimer Res 8(4): 330-335 (2011).
20. Lo CY, Wang PN, Chou KH, Wang J, He Y, Lin CP. Diffusion tensor tractography reveals abnormal topological organization in structural cortical networks in Alzheimer's disease. J Neurosci 30(50): 16876-16885 (2010).
21. Fernández J, Rojo L, Kuljis RO, Maccioni RB. The Damage Signals hypothesis of Alzheimer's disease. J Alzheimer's Dis 14(3):329-333 (2008).
22. Kuljis RO. Salkovic-Petrisic M. Dementia, diabetes, Alzheimer's disease and insulin resistance in the brain: Progress, dilemmas, new opportunities and a hypothesis to tackle intersecting epidemics. J Alzheimer's Dis 25: 29-41 (2011).
23. Leão RN, Colom LV, Borgius L, Kiehn O, Fisahn A. Medial septal dysfunction by Ap-induced KCNQ channel-block in glutamatergic neurons. Neurobiol Aging 33(9): 2046-61 (2012).
24. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1):106-113 (2008).
25. Woodruff-Pak DS. Animal models of Alzheimer's disease: therapeutic implications. J. Alzheimers Dis 15(4): 507-521 (2008).
26. Sarasa M, Pesini P. Natural non-trasgenic animal models for research in Alzheimer's disease. Curr Alzheimer Res 6(2):171-178 (2009).
27. Braidy N, Muñoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung RS, et al. Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm 119(2): 173-95 (2012).
28. Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Progress in Neurobiology 97: 38-51 (2012).
29. Colom LV, Castañeda MT, Bañuelos C, Puras G, García-Hernández A, Hernandez S, et al. Medial septal P-amyloid 1-40 injections alter septo-hippocampal anatomy and function. Neurobiol Aging 31(1): 46-57 (2010).
30. Colom LV, Castaneda MT, Hernandez S, Perry G, Jaime S, Tou-hami A. Intrahippocampal amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats. Curr Alzheimer Res 8(8): 832-840 (2011).
31. Bland BH, Colom LV. Extrinsic and intrinsic properties underlying oscillation and synchrony in limbic cortex. Prog Neurobiol 41: 157-208 (1993).
32. Colom LV. Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease. J Neurochem 96(3): 609-624 (2006).
33. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2(8000): 1403 (1976).
34. Henke H, Lang W. Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of Alzheimer-type patients. Brain Res 267(2): 281-291 (1983).
35. Geula C, Nagykery N, Nicholas A, Wu CK. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol 67(4): 309-318 (2008).
36. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221(2): 555-563 (2010).
37. Lynch G, Rose G, Gall C. Anatomical and functional aspects of the septo-hippocampal projections. Ciba Found Symp 58: 5-24 (1977).
38. Kohler C, Chan-Palay V, Wu JY. Septal neurons containing glutamic acid decarboxylase immunoreactivity project to the hippo-campal region in the rat brain. Anat Embryol 169: 41-44 (1984).
39. Colom LV, Castaneda MT, Reyna T, Hernandez S, Garrido-Sanabria E. Characterization of medial septal glutamatergic neurons and their projection to the hippocampus. Synapse 58(3): 151-164 (2005).
40. Vinogradova OS. Expression, control, and probable functional significance of the neuronal theta-rhythm. Prog Neurobiol 45: 523-583 (1995).
41. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, et al. amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res Brain Res Rev 43(1): 1-16 (2003).
42. Bonda DJ, Lee HG, Blair JA, Zhu X, Perry G, Smith MA. Role of metal dyshomeostasis in Alzheimer's disease. Metallomics 3(3): 267-270 (2011).
43. Terry RD. Cell death or synaptic loss in Alzheimer disease. J Neu-ropathol Exp Neurol 59(12): 1118-1119 (2000).
44. Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59(4-5): 332-345 (2007).
45. Finder VH, Glockshuber R. amyloid-β aggregation. Neurodegener Dis 4(1): 13-27 (2007).
46. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-842 (2008).
47. Kubo T, Nishimura S, Kumagae Y, Kaneko I. In vivo conversion of racemized P-amyloid ([D-Ser 26]Ap 1-40) to truncated and toxic fragments ([D-Ser 26]Ap 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70(3): 474-483 (2002).
48. Millucci L, Ghezzi L, Bernardini G, Santucci A. Conformations and biological activities of amyloid p peptide 25-35. Curr Protein Pept Sci 11(1): 54-67 (2010).
49. 2+ interaction with Alzheimer amyloid p protein calcium channels. Proc Natl Acad Sci USA 93(4): 1710-1715 (1996).
50. Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG. Syn-aptotoxicity of Alzheimer p amyloid can be explained by its membrane perforating property. PLoS One 5(7): e11820 (2010).
51. Colom LV, Diaz ME, Beers DR, Neely A, Xie WJ, Appel SH. Role of potassium channels in amyloid-induced cell death. J Neurochem 70(5):1925-1934 (1998).
52. Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29(4): 918-929 (2009).
53. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, et al. Amyloid p oligomers induce impairment of neuronal insulin receptors. FASEB J 22(1): 246-260 (2008).
54. Ondrejcak T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ. Alzheimer's disease amyloid P-protein and synaptic function. Neuromolecular Med 12(1):13-26 (2010).
55. Takeda S, Sato N, Rakugi H, Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: P-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst 7(6):1822-1827 (2011).
56. Pigino G, Morfini G, Atagi Y, Deshpande A, Yu C, Jungbauer L, et al. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid p. Proc Natl Acad Sci USA 106(14): 5907-5912 (2009).
57. Parodi J, Sepúlveda FJ, Roa J, Opazo C, Inestrosa NC, Aguayo LG. P-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol Chem 285(4): 2506-2514 (2010).
58. + channels in normal and diseased brains. Neuroscientist 16(1): 51-64 (2010).
59. Noebels J. A perfect storm: Converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia 52(1): 39-46 (2011).
60. + current in rat hippocampal neurons. Biophys J 70(1): 296-304 (1996).
61. + channel openers protect hippocampal neurons against oxidative injury and amyloid P-peptide toxicity. Brain Res 706(2): 328-332 (1996).
62. Yu SP, Farhangrazi ZS, Ying HS, Yeh CH, Choi DW. Enhancement of outward potassium current may participate in P-amyloid peptide-induced cortical neuronal death. Neurobiol Dis 5(2): 81-88 (1998).
63. Jhamandas JH, Cho C, Jassar B, Harris K, MacTavish D, Easaw J. Cellular mechanisms for amyloid P-protein activation of rat cholinergic basal forebrain neurons. J Neurophysiol 86(3): 1312-1320 (2001).
64. + channel currents in primary cultures of rat cerebellar granule and cortical neurones. J Neurochem 79(3): 699-712 (2001).
65. + currents in neocortical cultures. Neurobiol Dis 13(3): 177-190 (2003).
66. + current. Neurobiol Aging 27(11):1673-1683 (2006).
67. Coles B, Wilton LA, Good M, Chapman PF, Wann KT. Potassium channels in hippocampal neurones are absent in a transgenic but not in a chemical model of Alzheimer's disease. Brain Res 1190: 1-14 (2008).
68. Hou JF, Cui J, Yu LC, Zhang Y. Intracellular amyloid induces impairments on electrophysiological properties of cultured human neurons. Neurosci Lett 462(3): 294-299 (2009).
69. + channels depresses basal synaptic transmission in the hippocampal CA1 area in APP (swe/ind) TgCRND8 mice. Neurobiol Aging 31(4): 591-604 (2010).
70. Morley JE, Farra SA, Banks WA, Johnson SN, Yamadac KA, Xuc L. A physiological role for amyloid-β protein: enhancement of learning and memory. J Alzheimers Dis 19: 441-449 (2010).
71. Dickstein DL, Kabaso D, Rocher AB, Luebke JI, Wearne SL, Hof PR. Changes in the structural complexity of the aged brain. Aging Cell 6(3): 275-284 (2007).
72. Morley JE, Farr SA. Hormesis and amyloid-β protein: physiology or pathology? J Alzheimers' Dis 29(3): 487-492 (2012).